Zacks Investment Research downgraded Cidara Therapeutics Inc (NASDAQ:CDTX) to Sell in a statement released earlier today.
- Updated: March 20, 2017
Zacks Investment Research has downgraded Cidara Therapeutics Inc (NASDAQ:CDTX) to Sell in a statement released on 03/20/2017.
On Thursday February 23, 2017, Zacks Investment Research released a statement for Cidara Therapeutics Inc (NASDAQ:CDTX) bumped up the target price from $0.00 to $8.00 that suggested an upside of 0.13%.
Boasting a price of $7.10, Cidara Therapeutics Inc (NASDAQ:CDTX) traded -0.70% lower on the day. With the last stock price close down -29.59% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Cidara Therapeutics Inc has recorded a 50-day average of $8.64 and a two hundred day average of $10.08. Volume of trade was up over the average, with 258,551 shares of CDTX changing hands over the typical 77,969
See Chart Below
Cidara Therapeutics Inc has a 52 week low of $6.65 and a 52 week high of $15.91 The company’s market cap is currently $0.
General Information About Cidara Therapeutics Inc (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.